Combinatorial Use of Therapeutic ELP-Based Micelle Particles in Tissue Engineering

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Nanotechnology

Background:

• Chronic wounds pose a significant global health challenge.
• Current treatments often lack efficacy due to uncontrolled drug release and degradation of therapeutics.
• A combinatorial approach is needed to address multiple facets of wound healing simultaneously.

Purpose of the Study:

• To engineer micelle-forming elastin-like peptides (ELPs) conjugated with therapeutic molecules for wound healing.
• To create a nanoparticle system for sustained and controlled delivery of growth factors and antimicrobial peptides.
• To evaluate the efficacy of this combinatorial therapy in a preclinical wound model.

Main Methods:

• Genetically fusing micelle-forming ELP chains with keratinocyte growth factor (KGF), stromal cell-derived growth factor 1 (SDF1), and cathelicidin (LL37).
• Characterizing the micelle structure and in vitro bioactivity of the conjugated therapeutic moieties.
• Assessing wound closure efficacy in diabetic mice treated with ELP-nanoparticles compared to naked therapeutics.

Main Results:

• Conjugation of KGF, SDF1, and LL37 to ELPs did not disrupt micelle formation.
• All three therapeutic molecules retained their bioactivity in vitro after conjugation.
• ELP-nanoparticle treatment resulted in over 90% wound closure in diabetic mice, significantly outperforming naked therapeutics.

Conclusions:

• Micelle-forming ELPs provide a robust platform for delivering multiple therapeutic agents for wound healing.
• The developed ELP-nanoparticles demonstrate synergistic effects, enhancing wound closure.
• This represents a novel combinatorial therapy approach for effectively targeting chronic wound healing.